Gilead tracks five years of HIV grant giv­ing in hard-hit US South, and dou­bles down on new ap­proach­es

Gilead Sci­ences is now halfway through its 10-year pledge in the US south­ern states to tack­le HIV through com­mu­ni­ty grants, and look­ing back while al­so dou­bling down on new ap­proach­es to the still-grow­ing prob­lem.

Its Com­mit­ment to Part­ner­ship in Ad­dress­ing HIV in South­ern States (COM­PASS) is now aim­ing for an “eq­ui­ty-dri­ven ap­proach” in its grant-giv­ing and sup­port to or­ga­ni­za­tions.

South­ern states to­day ac­count for half of the deaths and 51% of the new cas­es of HIV in the US — even though on­ly one-third of the pop­u­la­tion lives there, Gilead says. How­ev­er, more con­cern­ing is the 30% de­crease since 2020 in peo­ple re­ceiv­ing treat­ment for HIV, “many of whom were Black Amer­i­cans who al­so shoul­dered a dis­pro­por­tion­ate share of con­se­quences of the Covid-19 pan­dem­ic,” said Dar­win Thomp­son, Gilead di­rec­tor of pub­lic af­fairs in a round­table dis­cus­sion on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER